&w=3840&q=100)
Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra
Glenmark Pharmaceuticals share price today: Pharmaceutical major Glenmark Pharmaceuticals shares rose as much as 2.74 per cent to hit an intraday high of ₹1,728 per share on Wednesday, June 25, 2025.
Around 1:05 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 1.82 per cent at ₹1,712.50 per share. In comparison, BSE Sensex was trading 0.71 per cent higher at 82,636.70 levels.
Why did Glenmark Pharmaceuticals share price rise today?
Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation (CDSCO).
Tevimbra is a uniquely engineered anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology innovator focused on delivering cutting-edge cancer therapies.
The drug is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and as a second-line monotherapy for both locally advanced/metastatic NSCLC and esophageal squamous cell carcinoma (ESCC).
The launch marks Glenmark Pharmaceuticals' entry into the immuno-oncology space in India and is a key step in broadening its oncology portfolio with innovative therapies.
NSCLC accounts for over 80 per cent of all lung cancer cases, while ESCC is the most prevalent histological subtype of esophageal cancer in India. Tevimbra addresses the major treatment needs of this large patient base with a differentiated and evidence-backed option, the company said.
Already approved and available in major markets including the US, EU, Australia, and China, Tevimbra is designed to selectively bind to PD-1 receptors, restoring T-cell function and limiting off-target immune suppression. It has shown strong efficacy and a favourable safety profile across various solid tumors in multiple Phase 3 studies and a global clinical programme.
Glenamark Pharmaceuticals Q4 results
For the fourth quarter of FY2024-25 (Q4FY25), Glenmark Pharmaceuticals reported a consolidated revenue of ₹3,256.2 crore, marking a year-on-year (Y-o-Y) growth of 6.3 per cent from ₹3,063 crore in the same period last year. The company's Ebitda for the quarter stood at ₹560.7 crore, up 11.2 per cent from ₹504.3 crore, with an Ebitda margin of 17.2 per cent. Adjusted Profit After Tax (PAT) for the quarter came in at ₹346.6 crore, reflecting an adjusted PAT margin of 10.6 per cent.
For the full fiscal year ended March 31, 2025 (FY25), the company's consolidated revenue rose 12.8 per cent to ₹13,321.7 crore, compared to ₹11,813.1 crore in the previous year. Ebitda for FY25 more than doubled to ₹2,351 crore from ₹1,195.3 crore, with the Ebitda margin improving to 17.6 per cent. The company also posted an adjusted PAT of ₹1,389.4 crore for the year, resulting in an adjusted PAT margin of 10.4 per cent.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a research-driven global pharmaceutical company with a strong presence across Branded, Generics, and OTC segments. The company focuses on key therapeutic areas including respiratory, dermatology, and oncology.
With 11 state-of-the-art manufacturing facilities spread across four continents and operations in over 80 countries, Glenmark Pharmaceuticals has established itself as a major player in the global pharmaceutical landscape.
The market capitalisation of Glenmark Pharmaceuticals is ₹48,171.68 crore, according to BSE. The company falls under the BSE 500 index.
Glenmark Pharmaceuticals' 52-week high is ₹1,830.05 per share, while its 52-week low is ₹1,199.95 apiece.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
38 minutes ago
- Time of India
Pharma companies may lose licence if drugs fail tests
Drugmakers will have to face strict government action if their products fail quality parameters and are declared as substandard. The punitive measure is being proposed by the health ministry during ongoing discussions with states to ensure quality drug production and safeguard public health. The ministry is looking to issue a notification shortly that will mandate immediate suspension of product licences of companies found producing 'not of standard quality' (NSQ) drugs by government laboratories, officials said. The Central Drugs Standard Control Organisation ( CDSCO ) on its part has been deliberating the matter with pharma lobby groups that have raised objections. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Victoria Principal Is Almost 75, See Her Now Reportingly Undo Earlier, the government's technical advisory board on drugs, which is part of CDSCO, had approved taking swift action against such manufacturers. Live Events "The board noted that it is very important that once a drug is declared NSQ, the license of such product shall be suspended immediately in public interest unless a satisfactory corrective action and preventive action (CAPA) is submitted by such manufactures. After detailed deliberation, DTAB recommended for the appropriate amendment in the Drug Rules in this regard and the suspension product licence should be revoked only after root cause analysis and corresponding CAPA has been implemented," according to the minutes of a board meeting of the technical advisory body. "The health ministry and the CDSCO is taking a step forward by taking views of the states and pharma bodies as it would require a notification," said a government official on the condition of anonymity. However, the pharma lobby groups have raised objections and given representations. NSQ, "is a global phenomenon, and most of the time, it is due to technical issues without any wrongful intent," the Federation of Pharma Entrepreneurs (FOPE) said in its representation. In a recent meeting, pharma lobby groups also pointed out that many government testing laboratories are facing challenges in following the current standards. "This has been a long-standing concern. It is also necessary that the NSQ investigation includes a review of records and data from government testing laboratories, as well as GLP compliance by the Drugs Inspector," a member of a lobby group opined. "It has been found that in many cases, samples declared NSQ by government labs, when challenged and tested by CDL Kolkata, have been declared as Standard Quality by CDL Kolkata, which is an appellate laboratory," the person said. Drug makers also emphasised that more than suspending licenses, it is crucial to strengthen the "recall mechanism". FOPE urged a proper impact analysis given the sensitivity of the matter. "We fear it may lead to malpractices in the profession, and genuine manufacturers with investments of hundreds of crores in plant setup, product development, technical team development, brand development, business development, and goodwill, may be adversely impacted if actions like the suspension of product permission are taken without proper investigation," the lobby group said.
News18
2 hours ago
- News18
Closing Bell: Sensex Surges 700 Points Higher, Nifty Above 25,200; Infosys Up 2%
Last Updated: Sensex Today: The Indian stock market is trading higher on Wednesday, supported by easing geopolitical tensions Sensex Today: Indian equity markets extended their winning streak for a second consecutive session on Wednesday, buoyed by strong buying in media and technology stocks. Investor sentiment improved amid easing crude oil prices and the announcement of a ceasefire between Iran and Israel. The BSE Sensex climbed 700.4 points, or 0.85 per cent, to close at 82,755.51, while the Nifty50 advanced 200.40 points, or 0.8 per cent, to end the day at 25,244.75. In the broader market, the Nifty MidCap index rose 0.44 per cent, and the Nifty SmallCap index outperformed with a gain of 1.5 per cent. Sectorally, the Nifty IT and Nifty FMCG indices outperformed, gaining 1.22 per cent and 0.8 per cent, respectively. Global Cues In global markets, Asia-Pacific indices traded largely flat after a positive start. Investor sentiment improved following a potential ceasefire between Iran and Israel, which was brokered by US President Donald Trump. The truce raised hopes of reduced geopolitical risks. At last check, Japan's Nikkei was up 0.073 per cent, while the broader Topix slipped 0.1 per cent. Meanwhile, Australia's ASX 200 and South Korea's Kospi were trading with a slight negative bias. Investors in the region are also awaiting Australia's May inflation data. In the US, stock futures were mostly muted during early Asian hours. Futures on the S\&P 500 and Nasdaq 100 each declined 0.1 per cent, while Dow futures also edged down by 0.1 per cent. Federal Reserve Chair Jerome Powell, in his latest remarks, said the central bank is likely to maintain interest rates amid ongoing inflation concerns and uncertainty over the impact of proposed tariffs. Powell noted that the Fed is 'well positioned to wait" before making any changes to monetary policy, reinforcing expectations of a longer pause on rate moves. US equity markets ended higher overnight, riding on the back of easing geopolitical risks and dovish Fed commentary. The Dow Jones Industrial Average jumped 1.19 per cent to 43,089.02. The S&P 500 gained 1.11 per cent to close at 6,092.18, just 0.9 per cent shy of its 52-week high. The Nasdaq Composite rose 1.43 per cent to 19,912.53, while the Nasdaq 100 surged 1.53 per cent to a record closing level of 22,190.52. First Published:
Time of India
3 hours ago
- Time of India
Skyroot Aerospace, Axiom Space team up to advance space exploration
HYDERABAD: On a day Axiom-4 (Ax-4) mission finally launched, carrying Group Captain Shubhanshu Shukla and three other astronauts to space, Hyderabad-based Skyroot Aerospace and US-based Axiom Space said they have signed a memorandum of understanding (MoU) to collaborate on advancing space exploration, particularly enhancing access to low earth orbit (LEO). Axiom Space will explore utilising Skyroot's capabilities for sending groundbreaking research payloads, orbital data center nodes, and other future missions to its under-construction Axiom Station as well as independently to LEO, the two players said in a joint statement. The two companies will collaborate to cater to not just the Indian market but also international markets. Skyroot Aerospace, which was the first private player in South Asia to successfully send a rocket to space with Vikram-S sub-orbital launch vehicle in November 2022, is gearing up to send its first orbital rocket – Vikram-1 -- into space later this year. On Wednesday, Axiom Space launched Ax-4, marking India's second shot at human spaceflight and the country's first mission on board the International Space Station (ISS). The mission is also being seen as foundational for the construction and operation of its Axiom Station as the company tries to develop a diverse global supply chain through partnerships with companies like Skyroot Aerospace. 'Enabling greater and equitable access to space, be it for research institutes, startups, or national agencies, is the guiding mantra at Skyroot,' said Pawan Kumar Chandana, co-founder and CEO, Skyroot Aerospace. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với sàn môi giới tin cậy IC Markets Tìm hiểu thêm Undo 'As we begin realizing this vision with the upcoming maiden launch of Vikram-1, the partnership with Axiom Space builds an opportunity to explore integrated launch and orbital solutions that will shape humanity's future in space,' Chandana added. Axiom Space CEO Tejpaul Bhatia said: 'Since the day I visited Skyroot's facility two years ago, I knew our companies had to work together to define humanity's future in space. With our shared vision to transform access to space, we look forward to collaborating with Skyroot to serve the growing space ecosystem in India and globally.'
